Oppenheimer Predicts Significant Growth for Sagimet and Y-mAbs Therapeutics
Sagimet Biosciences has made significant progress with its flagship product, denifanstat, particularly in the treatment of F2/F3 MASH, a condition affecting approximately 22 million adults in the U.S. The Phase 2b FASCINATE-2 trial demonstrated denifanstat's strong efficacy profile without safety or tolerability issues. Sagimet is preparing for a Phase 3 trial by the end of the year and plans to include patients with F4 MASH. Additionally, denifanstat is being tested for acne treatment in China and as a combination therapy for recurrent glioblastoma multiforme (rGBM), showing promising Phase 2 results.
Y-mAbs Therapeutics, on the other hand, has gained attention for its SADA platform technology, which offers a precise method for targeting cancerous tumors. The company's approved drug, DANYELZA, is already contributing to its revenue stream, but the SADA platform, with its potential to minimize off-target radiation exposure, represents a significant advancement in oncology. Y-mAbs is conducting early-stage clinical trials for GD2-SADA and CD38-SADA, targeting solid tumors and Non-Hodgkin Lymphoma, respectively.
Oppenheimer analysts are optimistic about both companies, with Jay Olson rating Sagimet as an Outperform with a $30 price target, indicating a potential 583% gain. Jeff Jones similarly rates Y-mAbs as an Outperform, with a $23 price target suggesting a 144% upside. The overall consensus for both stocks is a Strong Buy, highlighting their potential in the biotech sector.